<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01880593</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 13-0365</org_study_id>
    <nct_id>NCT01880593</nct_id>
  </id_info>
  <brief_title>Ketamine Plus Lithium in Treatment-Resistant Depression</brief_title>
  <official_title>Ketamine Plus Lithium as a Novel Pharmacotherapeutic Strategy in Treatment-Resistant Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the antidepressant effect of ketamine when given
      repeatedly over a period of 1 week, as well as the use of Lithium as a relapse-prevention
      strategy for patients with treatment-resistant depression (TRD) who respond to an initial
      series of ketamine infusions. Ketamine is a Food and Drug Administration approved anesthetic
      (a drug used to produce loss of consciousness before and during surgery). Ketamine is not
      approved for the treatment of major depressive disorder and is considered experimental in
      this study. An additional purpose of this study is to research the effects of ketamine on
      brain function.

      You may qualify to take part in this research study because you have been diagnosed with
      major depressive disorder (MDD) and have not responded to past treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major Depressive Disorder (MDD) is a disabling medical illness and current monoaminergic
      treatments are slow to act and possess only limited efficacy. In this context, the discovery
      that the glutamate NMDA receptor antagonist ketamine is rapidly antidepressant (onset of
      action within hours) -- even in patients suffering from treatment-resistant depression (TRD)
      -- has ignited tremendous enthusiasm among clinicians, scientists and patients alike. A
      critical obstacle to the translation of this discovery into a novel treatment, however, is
      the limited duration of action following a course of ketamine (e.g. 1-2 weeks). The current
      project will address this important gap in medical knowledge by testing a rational
      neuropharmacological strategy designed to optimize and sustain the rapid antidepressant
      effects of ketamine. Driven by the recent characterization of the molecular mechanisms
      underpinning the antidepressant and neuroplasticity effects of ketamine, we will test the
      combination of ketamine plus lithium in patients with TRD using a randomized, double blind,
      placebo-controlled design. The primary aims of the project are (1) to test the efficacy of
      lithium-plus-ketamine compared to placebo-plus-ketamine as an antidepressant combination
      strategy in TRD and (2) to gather data on the safety and tolerability of the
      lithium-plus-ketamine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MADRS-S Score</measure>
    <time_frame>2 weeks after last ketamine infusion</time_frame>
    <description>The Montgomery Asberg Depression Rating Scale (MADRS-S) has 10-items which are based on mood symptoms over the past 7 days. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QIDS-SR Score</measure>
    <time_frame>2 weeks after last ketamine infusion</time_frame>
    <description>Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) score - Each item is rated 0 (no depression) to 3 (severe depression), for a total score range of 0 (no depression) to 27 (severe depression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-S Score</measure>
    <time_frame>2 weeks after last ketamine infusion</time_frame>
    <description>The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAM-A Score</measure>
    <time_frame>2 weeks after last ketamine infusion</time_frame>
    <description>Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where &lt;17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BSS Score</measure>
    <time_frame>2 weeks after last ketamine infusion</time_frame>
    <description>BECK Scale for Suicidal Ideation (BSS) - 0-13 Minimal; 14-19 Mild; 20-28 Moderate; 29-63 Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSSRS Score</measure>
    <time_frame>2 weeks after last ketamine infusion</time_frame>
    <description>Columbia Suicide Severity Rating Scale (CSSRS) - Full range from 0 (low intensity suicidal ideation to 9 (high intensity suicidal ideation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Rated Inventory of Side Effects (PRISE)</measure>
    <time_frame>2 weeks after last ketamine infusion</time_frame>
    <description>Number of Participants with PRISE</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Ketamine and Lithium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm take 600-1200mg of Lithium pills at night for duration of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine and Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this arm take placebo pills at night for duration of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium</intervention_name>
    <description>Subjects in this arm take 600-1200mg of Lithium pills at night for duration of the study.</description>
    <arm_group_label>Ketamine and Lithium</arm_group_label>
    <other_name>Lithium Carbonate Immediate Release</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <arm_group_label>Ketamine and Lithium</arm_group_label>
    <arm_group_label>Ketamine and Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects in this arm take placebo pills at night for duration of the study.</description>
    <arm_group_label>Ketamine and Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients, 21-65 years of age;

          -  Female individuals who are not of childbearing potential (i.e., surgically sterile,
             postmenopausal for at least one year) or using a medically accepted reliable means of
             contraception. Women using oral contraceptive medication for birth control must also
             be using a barrier contraceptive. Women of childbearing potential must also have a
             negative serum B-HCG at screening and at pre-infusion;

          -  Participants must fulfill DSM-IV criteria for Major Depression without psychotic
             features, based on clinical assessment by a study psychiatrist and confirmed by a
             structured diagnostic interview, the Structured Clinical Interview for DSM-IV TR Axis
             I Disorders, Patient Edition (SCID-P);

          -  Participants must have a history of at least one previous episode of depression prior
             to the current episode (recurrent MDD) or have chronic MDD (of at least two years'
             duration);

          -  Participants have not responded to two or more adequate trials of an antidepressant as
             determined by Antidepressant Treatment History Form (ATHF) criteria (score &gt;=3);

          -  Current Major Depressive Episode of at least moderate severity, defined as a QIDS-SR
             score ≥ 14 and a CGI-S score of ≥ 4;Current major depressive episode is of at least 4
             weeks duration;

          -  Each participant must have a level of understanding sufficient to agree to all tests
             and examinations required by the protocol and must sign an informed consent document;

          -  Each participant must be able to identify a family member, physician, or friend who
             will participate in the Treatment Contract.

        Exclusion Criteria:

          -  Lifetime history of psychotic features, diagnosis of schizophrenia or any other
             psychotic disorder, or diagnosis of bipolar disorder;

          -  Lifetime histories of autism, mental retardation, pervasive developmental disorders,
             or Tourette's syndrome;

          -  Current diagnosis of OCD or eating disorder (bulimia nervosa or anorexia nervosa);

          -  Subjects with DSM-IV drug or alcohol abuse/dependence within the preceding 2 years;

          -  Patients with schizotypal or antisocial personality disorder, or any clinically
             significant axis II disorder that would, in the investigator's judgment, preclude safe
             study participation;

          -  Patients judged clinically to be at serious and imminent suicidal or homicidal risk;

          -  Women who are either pregnant or nursing;

          -  Serious, unstable medical illnesses including hepatic, renal impairment,
             gastroenterologic (including gastro-esophageal reflux disease), respiratory (including
             obstructive sleep apnea, or history of difficulty with airway management during
             previous anesthetics), cardiovascular (including ischemic heart disease and
             uncontrolled hypertension), endocrinologic, neurologic (including history of severe
             head injury), immunologic, or hematologic disease;

          -  Clinically significant abnormal findings of laboratory parameters, physical
             examination, or ECG;

          -  Patients who have a positive urine toxicology for illicit substances at screening and
             within 24 hours of the infusion;

          -  Patients with one or more seizures without a clear and resolved etiology;

          -  Treatment with an irreversible MAOI within 2 weeks prior to randomization or
             fluoxetine within 4 weeks prior to randomization;

          -  Treatment with other antidepressants within one week of randomization;

          -  Previous recreational use of PCP or ketamine;

          -  Hypertension (systolic BP &gt;160 mm Hg or diastolic BP &gt;90 mm Hg) not controlled by
             diuretic or beta-blocker therapy alone or in combination;

          -  A blood pressure reading over 160/90 or two separate readings over 140/90 at screening
             or baseline visits;

          -  Renal impairment, as reflected by a BUN &gt; 20 mg/dL and/or creatinin clearance of &gt;1.3
             mg/dL;

          -  Thyroid impairment, as reflected by a TSH &gt; 4.2 mU/L;

          -  Cardiac disease, as reflected by an EKG that is abnormal and of concern for cardiac
             disease;

          -  Any anticipated change in medications that could affect fluid or salt balance,
             including the following antihypertensive agents: ACE inhibitor, loop diuretics,
             calcium channel blockers, thiazide diuretics, angiotensin II receptor blockers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James W Murrough, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mssm.edu/map</url>
    <description>Mood and Anxiety Disorders Program</description>
  </link>
  <reference>
    <citation>Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013 Aug 15;74(4):250-6. doi: 10.1016/j.biopsych.2012.06.022. Epub 2012 Jul 27.</citation>
    <PMID>22840761</PMID>
  </reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 14, 2013</study_first_submitted>
  <study_first_submitted_qc>June 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2013</study_first_posted>
  <results_first_submitted>January 8, 2018</results_first_submitted>
  <results_first_submitted_qc>July 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2018</results_first_posted>
  <last_update_submitted>July 5, 2018</last_update_submitted>
  <last_update_submitted_qc>July 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>James Murrough</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>glutamate</keyword>
  <keyword>N-methyl-D-aspartate</keyword>
  <keyword>depression</keyword>
  <keyword>major depressive disorder</keyword>
  <keyword>treatment resistant</keyword>
  <keyword>antidepressant</keyword>
  <keyword>lithium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Lithium Carbonate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment from May 2013 through Sept 2016</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ketamine and Lithium</title>
          <description>600-1200mg of Lithium pills at night for duration of the study</description>
        </group>
        <group group_id="P2">
          <title>Ketamine and Placebo</title>
          <description>Placebo pills at night for duration of the study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine and Lithium</title>
          <description>600-1200mg of Lithium pills at night for duration of the study</description>
        </group>
        <group group_id="B2">
          <title>Ketamine and Placebo</title>
          <description>Placebo pills at night for duration of the study</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="12.65"/>
                    <measurement group_id="B2" value="45.87" spread="10.94"/>
                    <measurement group_id="B3" value="45.41" spread="11.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MADRS</title>
          <description>The Montgomery-Asberg Depression Rating Scale (MADRS) has 10-items which are based on mood symptoms over the past 7 days. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.39" spread="3.87"/>
                    <measurement group_id="B2" value="32.81" spread="5.61"/>
                    <measurement group_id="B3" value="32.58" spread="4.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>QIDS</title>
          <description>Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) score - Each item is rated 0 to 3. The total score ranges from 0 (no depression) - 27 (severe depression).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.22" spread="4.33"/>
                    <measurement group_id="B2" value="18.19" spread="3.082"/>
                    <measurement group_id="B3" value="17.16" spread="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CGI-S</title>
          <description>The Clinical Global Impression – Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.66" spread=".59"/>
                    <measurement group_id="B2" value="5" spread=".52"/>
                    <measurement group_id="B3" value="4.92" spread=".57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BSS</title>
          <description>BECK Scale for Suicidal Ideation (BSS) - 0-13 Minimal; 14-19 Mild; 20-28 Moderate; 29-63 Severe</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.89" spread="7.71"/>
                    <measurement group_id="B2" value="7.56" spread="8.31"/>
                    <measurement group_id="B3" value="7.24" spread="8.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HAM-A</title>
          <description>Hamilton Anxiety Rating Scale (HAM-A). Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0–56, where &lt;17 indicates mild severity, 18–24 mild to moderate severity and 25–30 moderate to severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.78" spread="7.02"/>
                    <measurement group_id="B2" value="20.31" spread="5.11"/>
                    <measurement group_id="B3" value="19.5" spread="6.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CSSRS (lifetime)</title>
          <description>The Columbia-Suicide Severity Rating Scale (C-SSRS) - Full range from 0 (low intensity suicidal ideation to 9 (high intensity suicidal ideation).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" spread="2.7"/>
                    <measurement group_id="B2" value="2.06" spread="2.02"/>
                    <measurement group_id="B3" value="2.29" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>MADRS-S Score</title>
        <description>The Montgomery Asberg Depression Rating Scale (MADRS-S) has 10-items which are based on mood symptoms over the past 7 days. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression).</description>
        <time_frame>2 weeks after last ketamine infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine and Lithium</title>
            <description>600-1200mg of Lithium pills at night for duration of the study</description>
          </group>
          <group group_id="O2">
            <title>Ketamine and Placebo</title>
            <description>Placebo pills at night for duration of the study</description>
          </group>
        </group_list>
        <measure>
          <title>MADRS-S Score</title>
          <description>The Montgomery Asberg Depression Rating Scale (MADRS-S) has 10-items which are based on mood symptoms over the past 7 days. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.56" spread="11.22"/>
                    <measurement group_id="O2" value="23" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QIDS-SR Score</title>
        <description>Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) score - Each item is rated 0 (no depression) to 3 (severe depression), for a total score range of 0 (no depression) to 27 (severe depression).</description>
        <time_frame>2 weeks after last ketamine infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine and Lithium</title>
            <description>600-1200mg of Lithium pills at night for duration of the study</description>
          </group>
          <group group_id="O2">
            <title>Ketamine and Placebo</title>
            <description>Placebo pills at night for duration of the study</description>
          </group>
        </group_list>
        <measure>
          <title>QIDS-SR Score</title>
          <description>Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) score - Each item is rated 0 (no depression) to 3 (severe depression), for a total score range of 0 (no depression) to 27 (severe depression).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.89" spread="6.04"/>
                    <measurement group_id="O2" value="10.13" spread="6.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGI-S Score</title>
        <description>The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.</description>
        <time_frame>2 weeks after last ketamine infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine and Lithium</title>
            <description>600-1200mg of Lithium pills at night for duration of the study</description>
          </group>
          <group group_id="O2">
            <title>Ketamine and Placebo</title>
            <description>Placebo pills at night for duration of the study</description>
          </group>
        </group_list>
        <measure>
          <title>CGI-S Score</title>
          <description>The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.83" spread=".86"/>
                    <measurement group_id="O2" value="3.875" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HAM-A Score</title>
        <description>Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where &lt;17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.</description>
        <time_frame>2 weeks after last ketamine infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine and Lithium</title>
            <description>600-1200mg of Lithium pills at night for duration of the study</description>
          </group>
          <group group_id="O2">
            <title>Ketamine and Placebo</title>
            <description>Placebo pills at night for duration of the study</description>
          </group>
        </group_list>
        <measure>
          <title>HAM-A Score</title>
          <description>Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where &lt;17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="8.15"/>
                    <measurement group_id="O2" value="11.13" spread="6.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BSS Score</title>
        <description>BECK Scale for Suicidal Ideation (BSS) - 0-13 Minimal; 14-19 Mild; 20-28 Moderate; 29-63 Severe</description>
        <time_frame>2 weeks after last ketamine infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine and Lithium</title>
            <description>600-1200mg of Lithium pills at night for duration of the study</description>
          </group>
          <group group_id="O2">
            <title>Ketamine and Placebo</title>
            <description>Placebo pills at night for duration of the study</description>
          </group>
        </group_list>
        <measure>
          <title>BSS Score</title>
          <description>BECK Scale for Suicidal Ideation (BSS) - 0-13 Minimal; 14-19 Mild; 20-28 Moderate; 29-63 Severe</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.94" spread="7.35"/>
                    <measurement group_id="O2" value="2.69" spread="5.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CSSRS Score</title>
        <description>Columbia Suicide Severity Rating Scale (CSSRS) - Full range from 0 (low intensity suicidal ideation to 9 (high intensity suicidal ideation).</description>
        <time_frame>2 weeks after last ketamine infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine and Lithium</title>
            <description>600-1200mg of Lithium pills at night for duration of the study</description>
          </group>
          <group group_id="O2">
            <title>Ketamine and Placebo</title>
            <description>Placebo pills at night for duration of the study</description>
          </group>
        </group_list>
        <measure>
          <title>CSSRS Score</title>
          <description>Columbia Suicide Severity Rating Scale (CSSRS) - Full range from 0 (low intensity suicidal ideation to 9 (high intensity suicidal ideation).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".833" spread="2.12"/>
                    <measurement group_id="O2" value=".44" spread=".89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Rated Inventory of Side Effects (PRISE)</title>
        <description>Number of Participants with PRISE</description>
        <time_frame>2 weeks after last ketamine infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine and Lithium</title>
            <description>600-1200mg of Lithium pills at night for duration of the study</description>
          </group>
          <group group_id="O2">
            <title>Ketamine and Placebo</title>
            <description>Placebo pills at night for duration of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Rated Inventory of Side Effects (PRISE)</title>
          <description>Number of Participants with PRISE</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ketamine and Lithium</title>
          <description>600-1200mg of Lithium pills at night for duration of the study</description>
        </group>
        <group group_id="E2">
          <title>Ketamine and Placebo</title>
          <description>Placebo pills at night for duration of the study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. James Murrough</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-7574</phone>
      <email>james.murrough@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

